DK0910400T3 - Terapier for kronisk nyresvigt - Google Patents

Terapier for kronisk nyresvigt

Info

Publication number
DK0910400T3
DK0910400T3 DK97923567T DK97923567T DK0910400T3 DK 0910400 T3 DK0910400 T3 DK 0910400T3 DK 97923567 T DK97923567 T DK 97923567T DK 97923567 T DK97923567 T DK 97923567T DK 0910400 T3 DK0910400 T3 DK 0910400T3
Authority
DK
Denmark
Prior art keywords
chronic kidney
kidney failure
risk
treatment
failure therapies
Prior art date
Application number
DK97923567T
Other languages
Danish (da)
English (en)
Inventor
Kuber T Sampath
Charles M Cohen
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK0910400T3 publication Critical patent/DK0910400T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK97923567T 1996-05-06 1997-05-06 Terapier for kronisk nyresvigt DK0910400T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
PCT/US1997/007655 WO1997041880A1 (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure

Publications (1)

Publication Number Publication Date
DK0910400T3 true DK0910400T3 (da) 2003-11-24

Family

ID=24580305

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97923567T DK0910400T3 (da) 1996-05-06 1997-05-06 Terapier for kronisk nyresvigt
DK97922726T DK0914146T3 (da) 1996-05-06 1997-05-06 Morfogenbehandling af kronisk nyresvigt

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97922726T DK0914146T3 (da) 1996-05-06 1997-05-06 Morfogenbehandling af kronisk nyresvigt

Country Status (11)

Country Link
US (5) US6498142B1 (es)
EP (2) EP0914146B1 (es)
JP (4) JP2000510835A (es)
AT (2) ATE277629T1 (es)
AU (2) AU2832297A (es)
CA (2) CA2254953C (es)
DE (2) DE69723845T2 (es)
DK (2) DK0910400T3 (es)
ES (2) ES2203803T3 (es)
PT (2) PT910400E (es)
WO (2) WO1997041881A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
CA2289123A1 (en) 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies for acute renal failure
AU7473098A (en) * 1997-05-07 1998-11-27 Biogen, Inc. Novel therapies for cystic kidney disease
DE69714035T2 (de) 1997-08-14 2003-03-06 Sulzer Innotec Ag Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
AU1706499A (en) * 1997-12-04 1999-06-16 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
BR9912548A (pt) * 1998-07-28 2002-01-29 Univ Johns Hopkins Med Fator-11 de diferenciação de crescimento
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
NZ517781A (en) * 1999-09-14 2004-01-30 Biogen Inc Therapies for chronic renal failure using one or more integrin antagonists
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
JP2006516020A (ja) * 2002-08-28 2006-06-15 キュリス インコーポレイテッド 慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与
DK1677735T3 (da) 2003-10-17 2014-10-27 Joslin Diabetes Center Inc Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
CA2557848C (en) 2004-03-30 2013-12-10 Ilypsa, Inc. Ion binding compositions
CA2561809A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
US20100150885A1 (en) * 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
WO2007056614A1 (en) 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
WO2007087570A2 (en) 2006-01-24 2007-08-02 Northfield Laboratories, Inc. Polymerized hemoglobin media and its use in isolation and transplantation of islet cells
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
US20090197280A1 (en) 2006-05-30 2009-08-06 Kristian Bangert Methods and Devices for Rapid Assessment of Severity of Injury
US7722665B2 (en) 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
EP2574625B1 (en) * 2006-07-21 2015-02-25 HuBit genomix, Inc. Remedy for renal disease
US20080255181A1 (en) * 2006-12-15 2008-10-16 University Of Heidelberg Methods for treating podocyte-related disorders
WO2008134297A2 (en) * 2007-04-24 2008-11-06 Johnson & Johnson Regenerative Therapeutics, Llc Engineered renal tissue
DE102007034580B4 (de) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
WO2009137613A2 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
JP5485885B2 (ja) * 2008-06-24 2014-05-07 株式会社根本杏林堂 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
BRPI0917711A2 (pt) * 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
EP2813848A3 (en) * 2008-08-29 2015-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20110207161A1 (en) * 2008-10-21 2011-08-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628843A (en) * 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2913676A1 (en) 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102272328B (zh) * 2008-11-22 2014-06-18 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BRPI1007917A2 (pt) * 2009-02-06 2019-09-24 Astute Medical Inc método para avaliar a situação renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
JP5819734B2 (ja) * 2009-02-12 2015-11-24 ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ ＴＧＦ−βスーパーファミリーメンバー含有タンパク質の最小に侵襲性の全身送達のための組成物および方法
US20100204123A1 (en) * 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
EP2406281B1 (en) * 2009-03-12 2016-02-17 Haase Investments UG Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
MX336280B (es) 2009-08-07 2016-01-13 Astute Medical Inc Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
EP2352750B1 (en) 2009-09-17 2012-06-13 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
CN104793000A (zh) 2009-11-07 2015-07-22 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
ES2818138T3 (es) 2009-12-20 2021-04-09 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
WO2011087768A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
WO2011097539A1 (en) 2010-02-05 2011-08-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2790785A1 (en) 2010-02-26 2011-09-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011162819A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2576587B1 (en) 2010-05-24 2018-03-21 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
WO2012023113A2 (en) 2010-08-20 2012-02-23 Wyeth Llc Designer osteogenic proteins
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
BR112015007749A2 (pt) 2012-10-08 2017-07-04 Relypsa Inc métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica.
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
PT2946211T (pt) 2013-01-17 2018-06-04 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e insuficiência renal
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
JP2016536588A (ja) * 2013-11-11 2016-11-24 ゼネラル・エレクトリック・カンパニイ ロータ速度の測定における誤差を低減する方法
EP2944326B1 (en) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases
AU2016218977C1 (en) 2015-02-13 2023-03-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA3026502A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
JP2019528284A (ja) 2016-08-17 2019-10-10 ファクター バイオサイエンス インコーポレイテッド 核酸産物およびその投与方法
JP2019039673A (ja) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
ATE162223T1 (de) 1989-03-28 1998-01-15 Genetics Inst Osteoinduktive zusammensetzungen
CA2082941A1 (en) 1990-05-16 1991-11-17 Rodney M. Hewick Bone and cartilage inductive proteins
JPH0426624A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
EP0533840B1 (en) 1990-06-22 1996-12-11 E.I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
DK0575555T3 (da) 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
ATE308336T1 (de) 1991-08-30 2005-11-15 Curis Inc Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
ATE192931T1 (de) 1991-08-30 2000-06-15 Creative Biomolecules Inc Morphogen-induzierte modulation von entzündlichen antworten
EP0601129B1 (en) 1991-08-30 2000-11-15 Creative Biomolecules, Inc. Morphogenic protein screening method
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
JP4344012B2 (ja) 1992-07-31 2009-10-14 ストライカー・コーポレーション 組織形成因子誘導による神経の再生と修復
WO1994003075A2 (en) 1992-07-31 1994-02-17 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
WO1994003600A1 (en) 1992-07-31 1994-02-17 Creative Biomolecules, Inc. Morphogenic protein soluble complex and composition thereof
WO1994006449A2 (en) 1992-09-16 1994-03-31 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
AU681362B2 (en) 1992-11-03 1997-08-28 Stryker Corporation OP-3-induced morphogenesis
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
CA2157387C (en) 1993-03-04 1998-12-15 David C. Rueger Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
EP0894004B2 (en) * 1996-03-22 2007-02-21 Curis, Inc. Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
US8017580B2 (en) 2011-09-13
JP2009185076A (ja) 2009-08-20
US6498142B1 (en) 2002-12-24
US20120004171A1 (en) 2012-01-05
JP2000510124A (ja) 2000-08-08
US6861404B1 (en) 2005-03-01
EP0910400A1 (en) 1999-04-28
ES2203803T3 (es) 2004-04-16
US20050143304A1 (en) 2005-06-30
AU2832297A (en) 1997-11-26
EP0914146B1 (en) 2004-09-29
WO1997041880A1 (en) 1997-11-13
US7524817B2 (en) 2009-04-28
JP2012229268A (ja) 2012-11-22
CA2254954A1 (en) 1997-11-13
PT910400E (pt) 2003-12-31
DE69723845T2 (de) 2004-06-03
US20100291170A1 (en) 2010-11-18
JP2000510835A (ja) 2000-08-22
ATE245997T1 (de) 2003-08-15
DK0914146T3 (da) 2005-01-31
CA2254953C (en) 2006-09-26
DE69730966D1 (de) 2004-11-04
PT914146E (pt) 2005-02-28
EP0910400B1 (en) 2003-07-30
ES2230604T3 (es) 2005-05-01
CA2254954C (en) 2010-01-12
JP5247593B2 (ja) 2013-07-24
CA2254953A1 (en) 1997-11-13
JP4766722B2 (ja) 2011-09-07
DE69730966T2 (de) 2006-02-23
WO1997041881A1 (en) 1997-11-13
US8377878B2 (en) 2013-02-19
AU2933997A (en) 1997-11-26
EP0914146A1 (en) 1999-05-12
DE69723845D1 (de) 2003-09-04
ATE277629T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
DK0910400T3 (da) Terapier for kronisk nyresvigt
DE69432582T2 (de) System zur Administration von Flüssigkeiten bei mehreren Patienten
ATE278414T1 (de) Therapien zur behandlung von akutem nierenversagen
EA200500218A1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
MXPA03011386A (es) Proteina de union para su uso en la regeneracion de hueso o cartilago.
NO970536D0 (no) Behandlingssystem for avgitt blod med skrå reguleringsgrenseflate
IS2925B (is) Ákvörðun á batahorfum sjúklings sem undirgengst meðhöndlun við Alzheimer-sjúkdómi
NO982436D0 (no) Apparat for oppvarming av blod
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
DK52089A (da) Middel til behandling af nyresygdomme
DE69726345D1 (de) Apparat zur extrakorporalen Blutbehandlung
DK0751785T4 (da) Kombinationer af thrombolytisk aktive proteiner og antikoagulationsmidler samt anvendelse heraf
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
SE8902532L (sv) Bestaemning av plasmaproteiner
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
WO2004019876A3 (en) Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
HUP9801214A2 (hu) Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk
ATE361756T1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4 protease
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
ATE204169T1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung
ATE223227T1 (de) Verwendung von lbp zur sepsistherapie
DE59609353D1 (de) Mittel zur subkutanen Verabreichung von Protein C
UA29043A (uk) Спосіб визначення коагуляційної активності гемолізаткальцієвої суміші